pravastatin has been researched along with Cholelithiasis in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 13 (81.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Björkhem, I; Einarsson, C; Gustafsson, U; Hillebrant, CG; Nyberg, B; Rudling, M; Sahlin, S | 1 |
| Doornewaard, H; Edgar, P; Renooij, W; Smit, JW; Stolk, MF; van Erpecum, KJ; Vanberge-Henegouwen, GP | 1 |
| Chijiiwa, K; Ichimiya, H; Kishinaka, M; Kosahara, K; Kuroki, S; Nakano, K; Oda, H; Okamoto, S | 1 |
| Gadella, MM; Smit, JW; Van Berge-Henegouwen, GP; Van de Heyning, BJ; Van Erpecum, KJ | 1 |
| Baggio, G; Cianci, V; Crepaldi, G; Martini, S; Muraca, M; Vilei, MT | 1 |
| Agarwal, DK; Baijal, SS; Saraswat, VA; Sharma, BC | 1 |
| Axelson, M; Björkhem, I; Einarsson, C; Hillebrant, CG; Nyberg, B; Wang, FH | 1 |
| Caroli-Bosc, C; Caroli-Bosc, FX; Delabre, B; Delmont, JP; Demarquay, JF; Le Gall, P; Montet, JC; Pugliese, P; Rampal, P | 1 |
| Cluysenaer, OJ; Erkelens, DW; Geerdink, RA; Smit, JW; Stolk, MF; van Berge Henegouwen, GP; van Erpecum, KJ | 1 |
| Aihara, N; Hatsushika, S; Kajiyama, G; Mizuno, S; Sagawa, H; Sasaki, H; Sasaki, M; Tao, S; Tazuma, S; Yamashita, G | 1 |
| Pan, HY | 1 |
| Angelin, B; Berglund, L; Björkhem, I; Einarsson, K; Ewerth, S; Reihnér, E; Rudling, M; Ståhlberg, D | 2 |
| Angelin, B | 1 |
| Aihara, N; Hatsushika, S; Mizuno, S; Oya, T; Sagawa, H; Sasaki, H; Sasaki, M; Tazuma, S; Toge, S; Yamashita, G | 1 |
| Hayashi, K; Horiuchi, I; Kajiyama, G; Koide, K | 1 |
1 review(s) available for pravastatin and Cholelithiasis
| Article | Year |
|---|---|
Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.
Topics: Anticholesteremic Agents; Cholelithiasis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lactation; Liver Diseases; Naphthalenes; Pravastatin; Reference Values | 1991 |
5 trial(s) available for pravastatin and Cholelithiasis
| Article | Year |
|---|---|
Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
Topics: Adult; Aged; Anticholesteremic Agents; Bile; Case-Control Studies; Cholagogues and Choleretics; Cholelithiasis; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pravastatin; Receptors, LDL; RNA, Messenger; Ursodeoxycholic Acid | 2002 |
The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
Topics: Bile; Bile Acids and Salts; Body Mass Index; Cholecystectomy; Cholelithiasis; Cholesterol; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Phospholipids; Placebos; Pravastatin | 1995 |
Effect of withdrawal of pravastatin on biliary lipid composition in humans.
Topics: Adult; Anticholesteremic Agents; Bile; Bile Acids and Salts; Bile Ducts; Cholelithiasis; Cholesterol; Diet, Fat-Restricted; Double-Blind Method; Drainage; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Liver; Phospholipids; Pravastatin; Substance Withdrawal Syndrome; Triglycerides | 1996 |
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bile Acids and Salts; Bilirubin; Cholecystectomy; Cholelithiasis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Pravastatin; Triglycerides | 1998 |
[Effect of pravastatin on hepatic cholesterol metabolism].
Topics: Adult; Aged; Cholelithiasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL | 1991 |
10 other study(ies) available for pravastatin and Cholelithiasis
| Article | Year |
|---|---|
Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholelithiasis; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Crystallization; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Lipid Metabolism; Liver; Male; Middle Aged; Pravastatin; Time Factors; Ursodeoxycholic Acid | 1994 |
Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?
Topics: Anticholesteremic Agents; Bile; Cholagogues and Choleretics; Cholelithiasis; Cholesterol; Crystallization; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Phase-Contrast; Pravastatin; Taurodeoxycholic Acid; Time Factors | 1996 |
Pravastatin has no effect on bile lipid composition, nucleation time, and gallbladder motility in persons with normal levels of cholesterol.
Topics: Adult; Bile; Cholelithiasis; Cholesterol; Female; Gallbladder; Gallbladder Emptying; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pravastatin; Reference Values | 1997 |
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Topics: Anticholesteremic Agents; Cholelithiasis; Double-Blind Method; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pregnancy; Risk Factors; Simvastatin | 2001 |
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Topics: Cholelithiasis; Cholesterol; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Ultrasonography | 1992 |
Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs.
Topics: Animals; Bile; Bile Acids and Salts; Cholelithiasis; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phospholipids; Pravastatin; Sciuridae | 1992 |
Regulation of hepatic cholesterol metabolism in man.
Topics: Cholelithiasis; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Naphthalenes; Pravastatin; Receptors, LDL | 1991 |
[Effects of a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase on cholesterol gallstone formation in prairie dogs].
Topics: Animals; Cholelithiasis; Cholesterol; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Sciuridae | 1991 |
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Topics: Aged; Anticholesteremic Agents; Cholelithiasis; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Microsomes, Liver; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL; Sterol O-Acyltransferase | 1990 |
Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.
Topics: Animals; Anticholesteremic Agents; Bile; Bile Acids and Salts; Cholelithiasis; Cholesterol; Cricetinae; Dietary Carbohydrates; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Mesocricetus; Microsomes, Liver; Naphthalenes; Pravastatin; Reference Values; Triglycerides | 1989 |